December 8, 2025BloodOpen Access

First-line pola-R-CHP in diffuse large B cell lymphoma: A single-center real-world data analysis

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Analysis shows complete response of 47.5% in high-risk DLBCL patients, indicating challenges in real-world settings.

Progression-free survival at 12 months was 92.3% for the cohort, highlighting the treatment's potential efficacy.
Among high-risk patients, the study found significant variations in complete response rates by IPI score and TP53 status.
Next-generation sequencing identified alterations in TP53 in 39.2% of patients, underlining its relevance to treatment outcomes.
Socioeconomic factors may influence treatment access and response assessment, emphasizing the need for larger, extended studies.],

Jie Sun (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Analysis shows complete response of 47.5% in high-risk DLBCL patients, indicating challenges in real-world settings.

Progression-free survival at 12 months was 92.3% for the cohort, highlighting the treatment's potential efficacy.
Among high-risk patients, the study found significant variations in complete response rates by IPI score and TP53 status.
Next-generation sequencing identified alterations in TP53 in 39.2% of patients, underlining its relevance to treatment outcomes.
Socioeconomic factors may influence treatment access and response assessment, emphasizing the need for larger, extended studies.],

Jie Sun (2025) studied this question.

View Full Paper

Ask AI

Bookmark